力生制药：关于子公司中央药业药品阿普米司特片通过上市许可申请的公告

Core Viewpoint - Recently, the company announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., received drug registration certificates for Apremilast tablets in three different specifications: 10mg, 20mg, and 30mg, indicating successful approval for market entry [2]. Group 1 - The company has obtained the drug registration certificate for Apremilast tablets 10mg (Approval No. 2025S03538) [2] - The company has also received the drug registration certificate for Apremilast tablets 20mg (Approval No. 2025S03539) [2] - Additionally, the company secured the drug registration certificate for Apremilast tablets 30mg (Approval No. 2025S03540) [2]